Efficacy and tolerability of (oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life

Clinical Therapeutics

Volumn 18, Issue 3, 1996, Pages 508-518

  Crucitt, Michael A ^a   Hyman, William ^b   Grote, Thomas ^c   Tester, William ^d   Madajewicz, Stefan ^e   Yee, Sharon ^f   Wentz, Alison ^g   Griffin, Daniel ^g   Parasuraman, T V ^g   Bryson, Judy ^g  

^a Sharp Rees Stealy Medical Group   (United States)

^b TEXAS ONCOLOGY   (United States)

^c Salem Research Group   (United States)

^d ALBERT EINSTEIN CANCER CENTER   (United States)

^e STONY BROOK UNIVERSITY   (United States)

^f Shapiro Stafford and Yee MD   (United States)

^g GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; ONDANSETRON; PHENOTHIAZINE DERIVATIVE; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE; VINCRISTINE;

ADULT; AGED; APPETITE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 8944260898     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80032-4     Document Type: Article

References (13)

1. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. NEJM. 1993;22:810-816.
2. Gebbia V, Cannata G, Testa A, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting: Results of a prospective randomized trial. Cancer. 1994;74: 1945-1952.
3. Beck TM, Hesketh PJ, Madajewicz S, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1992;10: 1969-1975.
4. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. J Clin Oncol. 1990;8:1721-1727.
5. Beck TM, Ciociola AA, Jones SE, et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med. 1993;118:407-413.
6. Beck TM. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: Review of clinical trials. Semin Oncol. 1992;19(Suppl 15):20-25.
7. DiBenedetto J, Cubeddu L, Ryan T, et al. Twice daily oral ondansetron effectively prevents nausea and vomiting associated with cyclophosphamide-doxorubicin-based chemotherapy. Proc Am Soc Clin Oncol. 1995;14:538.
8. Beck T, York M, Chang A, et al. Oral ondansetron 8 mg BID is as effective as 8 mg TID in the prevention of nausea and vomiting associated with cyclophosphamide-based chemotherapy. Proc Am Soc Clin Oncol. 1995;14:538.
9. Schipper H, Clinch J, McMurray A, Levitt M. Measuring quality of life of cancer patients. The Functional Living Index - Cancer: Development and validation. J Clin Oncol. 1984;2:472-483.
10. Lindley CM, Hirsch JD, O'Neill CV, et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res. 1992;1:331-340.
11. Dicato MA, Kaasa S, Campora E, et al. Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy-induced emesis: A randomized, single-blind, multicentre study. Clin Oncol. 1992;4:275-279.
12. Graves T. Emesis as a complication of cancer chemotherapy: Pathophysiology, importance, and treatment. Pharmacotherapy. 1992;12:337-345.
13. Babowski MT. Advances in anti-emetic therapy. Cancer Treat Rev. 1984;11: 237-256.